Uromigos-Prostate Cancer

The UromigosThe Uromigos | November 7, 2022
The Uromigos chat with Axel Merseburger about his paper on continuing enzalutamide with docetaxel for the treatment of CRPC.
Read More
The UromigosThe Uromigos | November 2, 2022
Rob Jones discusses the current state of PARP inhibition in prostate cancer as well as differing opinions on the treatment.
The UromigosThe Uromigos | October 25, 2022
Silke Gillessen and Nick James discuss a randomized trial on duration of adjuvant/salvage androgen ablation with XRT. 
The UromigosThe Uromigos | August 1, 2022
Alex Wyatt joins The Uromigos to answer questions about ctDNA in prostate cancer and discuss his latest paper on that topic.
The UromigosThe Uromigos | July 26, 2022
Declan Murphy and Matt Cooperberg debate the use of interventions in active surveillance for patients with prostate cancer.
The UromigosThe Uromigos | July 18, 2022
Dr. Oliver Sartor, medical director of Tulane Cancer Center, discusses his career development and work in prostate cancer.
The UromigosThe Uromigos | June 20, 2022
Neal Shore describes his recent controversial paper and the over-treatment of patients with low-grade disease.
The UromigosThe Uromigos | June 20, 2022
Phillip Kuo discusses phase 3 of the VISION trial that utilizes Lutetium-177 for the treatment of prostate cancer.
The UromigosThe Uromigos | April 18, 2022
Drs. Rana McKay and Kim Chi question whether doublet or triplet therapy is appropriate in the first-line.
The UromigosThe Uromigos | April 6, 2022
Martin Stockler describes the ENZAMET trial, which shows mixed effects of enza on QOL in prostate cancer.
The UromigosThe Uromigos | February 28, 2022
Dr. Stefano Fanti focuses on PSMA therapy PET CT, particularly when to use this as a diagnostic.
The UromigosThe Uromigos | February 19, 2022
Dr. Fred Saad describes the results of the PROpel Phase III trial.
The UromigosThe Uromigos | February 17, 2022
Kim Chi, MD, describes the results of the MAGNITUDE trial,
The UromigosThe Uromigos | February 17, 2022
Results from the ARASENS trial appear to have confirmed triple therapy as the new standard of care for mHSPC.
The UromigosThe Uromigos | February 10, 2022
Pete Nelson, MD, describes mechanism of action and current clinical application in prostate cancer.
The UromigosThe Uromigos | December 6, 2021
Silke Gillessen and Chris Sweeney join Tom and Brian to give a year in review.
The UromigosThe Uromigos | October 27, 2021
Dr. Tanya Dorff discusses the TALAPRO-1 study and the role of PARP inhibitors in prostate cancer.
The UromigosThe Uromigos | September 19, 2021
Dr. Karim Fizazi summarizes PEACE-1 data and describes the OS benefit of the triplet.
The UromigosThe Uromigos | September 19, 2021
Dr. Gert Attard describes the practice-changing plenary data from the STAMPEDE study, presented at ESMO 2021.
The UromigosThe Uromigos | September 18, 2021
Dr. Neeraj Agarwal describes the COSMIC-21 study on cabozantinib and atezolizumab in prostate cancer patients.
Advertisement
Advertisement